J.V. Aranda

Publications & Grants

• Glibetic M, Samlalsingh-Parker J, Raykova V, Ofenstein J, Aranda JV. Group B Streptococci and inducible nitric oxide synthase: modulation by nuclear factor kappa B and ibuprofen. Semin Perinatol. 2001 Apr; 25(2):65-9.
• Raykova VD, Glibetic M, Ofenstein JP, and Aranda JV. Nitric oxide-dependent regulation of pro-inflammatory cytokines in Group B Streptococcal rat lung inflammation. Ann Clin Lab Sci. 2003; 33:62-7.
• Ergun H, Frattarelli DA, Aranda JV: Characterization of the role of physiochemical factors on the hydrolysis of dipyrone. J Pharm Biomed Anal. 2004 May 28;35(3):479-87.
• Kapur G, Mattoo T, Aranda JV. Pharmacogenomics and renal drug handling in newborns. Sem Perinatol. 2004.:28:132-140.
• Prescilla RP, Frattarelli DA, Haritos D, Aranda JV, Edwards DJ: Pharmacokinetics of Rofecoxib in Children With Sickle Cell Hemoglobinopathy. J Pediatr Hematol Oncol. 4004 Oct:26(10):661-664.
• Sood BG, Delaney-Black V, Aranda JV, Shankaran S: Aerosolized PGE1: A selective Pulmonary Vasodilator in Neonatal Hypoxemic Respiratory Failure Results of a Phase I/II Open Label Clinical Trial. Pediatr Res. 4004 Oct;56(4):579-85. Epub 2004 Aug 04.
• VanWoerkom R, Beharry K DA, Modanlou H, Parker J, Rajan V, Akmal Y, Aranda JV. Influence of morphine and Naloxone on endothelin and its receptors in newborn piglet brain vascular endothelial cells: clinical implications in neonatal care. Pediatric Research 2004: 55: 147-151.
• Jacobs RF, Maples HD, Aranda JV, Espinoza GM, Knirsch C, Chandra R, Fisher JM, Kearns GL. Pharmacokinetics of Intravenously Administered Azithromycin in Pediatric Patients. J Pediatr Infect Dis J. 2005 Jan:24(3):34-9.
• Thomas RL, Parker GC, Van Overmeire B, Aranda JV. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus.Eur J Pediatr. 2005 Mar;164(3):135-40. Epub 2004 Dec 10.
• Edwards DJ, Chugani DC, Chugani HT, Chehab J, Malian M, Aranda JV. Pharmacokinetics of Buspirone in autistic children. J Clin Pharmacol. 2006 May;46(5):508-14.
• Aranda JV, Carlo W, Hummel P, Thomas R, Lehr VT, Anand KJ.; Analgesia and sedation during mechanical ventilation in neonates Clin Ther. 2005 Jun;27(6):877- 899.
• Beharry KD, Modanlou HD, Hasan J, GHarraee Z, Abad-Santos P, Sills JH, Jan A, Nageotte S, Aranda JV. Comparative Effects of Early Postnatal Ibuprofen and Indomethacin on VEGF, IGF-I, and GH during Rat Ocular Development. Investigative Opthalmology & Visual Scince, 2006, Jul;47(7):3036-43.

Ongoing Research Support

5-U01HD-37261-01 (PI: J. V. Aranda, MD, PhD) — $1,984,324.00

1/1/2004 - 2/31/2008 30% NICHD Children's Center for Clinical Pharmacology Research-Pediatric Pharmacology Research Unit Network (PPRU) Competing Renewal

3U01HD-37261-04S1 Aranda (PI) — $200,000.00 9/2002-8/2003 (extended-2006)

NIH Targeted Drug Delivery Using Novel Polymeric Nanostructures, Applications in Asthma and Thrombolysis. Supplemental funding from the NICHD: 1) to study the effects of dendrimer-methylprednisolone complex delivered by aerosol in a mouse model of asthma, 2) to study the ability of antifibrin antibody-dendrimer-tissue plasminogen activator complex to dissolve clots induced in the internal jugular vein of rabbits.

Project PI: M. Lieh Lai

3U01HD-37261-04S2 Aranda (PI) — $200,000.00 9/2002-8/2003(extended 2006)

NIH Early Pharmacotherapy Aimed at Neuroplasticity in Autism.

Supplemental funding from the NICHD: 1) to determine the pharmacokinetic profile of Buspirone in young children, 2) to determine efficacy, safety and population PK of Buspirone in autistic children and 3) to determine the role of genetic polymorphism in drug response.

Project PI: D. Chugani

WOMC- 2005 Ontogeny of GABA receptors in Newborn Infants with Apnea ;PI: J. V. Aranda 1/1/2005- 12/31/2007 effort=10 % Role: Principal Investigator - J. V. Aranda

Gerber Foundation — $165,000.00 7/01/2007-7/01/2009

Adverse Drug Reaction Diagnostic Tool for the Newborn . Du, W- (PI) and J.V. Aranda, Co PI

NIH - 1R03 HD057566-01 J.V. Aranda (PI) (pending) 01/01/2008-01/01/2010

Absorption and Metabolism of Oral Codeine in Mechanically Ventilated Neonates

583E-URO-0581-006 — J.V. Aranda (PI) 6/19/02-6/30/04

Pharmacia & Upjohn Company An Open Label, Phase III, 12 Month Study of the Long-Term Clinical Efficacy, Safety and Tolerability of Tolterodine Oral Solution and PR Capsules in Children with Detrusor Hyperreflexia Ages 4 Months to 16 Years of Age.

FCR-00-01/Ross CB — J.V. Aranda (PI) 5/10/02-5/9/05

Farmacon, IL-LLC A Randomized Double Blind Study of Ibuprofen L-Lysinate Intravenous Solution in Premature Infants for the Early Treatment of PDA.

A06610491001 — J.V. Aranda (PI) 3/20/02-3/31/03

Pfizer, Inc.

An Open-Label Evaluation of the Pharmacokinetics and Safety of a Single 10mg/kg Dose of Intravenously Administered Azithromycin in Hospital Children.

C-2000-042/20012372 — J.V. Aranda (PI) 8/28/01-9/30/03

Alza Corporation

The Safety and Tolerability of Ocybutynin Chloride (Ditropan XL, Ditropan Syrup or Ditropan Tablets) in the Treatment of Detrusor Hyperreflexia Due to Neurogenic Conditions in Children).

B4Z-MC-LYAI — J.V. Aranda (PI) 6/13/01-6/30/03

Eli Lilly and Company, Lilly Research Laboratories

Long Term, Open-Label, Safety Study of Tomoxetine HCl in Patients, 6 Years and Older.

99-0-063 — J.V. Aranda (PI) 7/1/00-6/30/03

Fujisawa Healthcare, Inc.

Pharmacokinetic, Safety and Tolerance Study of Three Doses of FK463 in Premature Infants.

Pending Research Support

NIH-NIEHS: RO1: Lead In the pathogenesis of Pediatric Diabetes: Biomarkers, Mechanisms and Therapy.

• $ 11,985,253.00- total cost ( 07/01/2007 to 06/30/2012 -) PIs: Novak R and Aranda JV
• NIH: RO3: A multicenter Clinical Trial on the absorption and Metabolism of oral codeine in Mechanically ventrilated newborns.
• $195,091.00 Total cost ( 12-01-2007 to 11-30-2009) PI: Aranda JV and the PPRU Network

Completed Research Support

1-U01HD-37261 — J.V. Aranda (PI) 1999-2004

• NICHD Children's Center for Clinical Pharmacology Studies.
• The major goals of this project are to conduct studies on the metabolism and disposition of drugs in the pediatric population in order to provide improved guidelines and labeling of drugs for use in children.

583E-URO-0581-001 — J.V. Aranda (PI) 9/11/01-3/20/02

• Pharmacia & Upjohn Company Phase I/II, Open Label, Dose-Escalating Pharmacokinetic, Pharmacodynamic (Urodynamic) and Clinical Effect, and Safety Study of Tolterodine PR Capsules in Children with Detrusor Hyperreflexia 1 Month to 4 Years of Age.

583E-URO-0581-002 — J.V. Aranda (PI) 9/11/01-3/20/02

• Pharmacia & Upjohn Company Phase I/II, Open Label, Dose-Escalating Pharmacokinetic, Pharmacodynamic (Urodynamic) and Clinical Effect, and Safety Study of Tolterodine PR Capsules in Children with Detrusor Hyperreflexia 5 to 10 Years of Age.

583E-URO-0581-003 — J.V. Aranda (PI) 9/11/01-3/20/02

• Pharmacia & Upjohn Company Phase I/II, Open Label, Dose-Escalating Pharmacokinetic, Pharmacodynamic (Urodynamic) and Clinical Effect, and Safety Study of Tolterodine PR Capsules in Children with Detrusor Hyperreflexia 11 to 15 Years of Age.

B4Z-MC-LYAQ — J.V. Aranda (PI) 1/11/01-1/31/03

• Lilly Research Laboratories Safety and Efficacy of Tomoxetine or Tomoxetine Plus Fluosetine in the Treatment of Mixed Attentional and Affective Disorders.

PO1392-65 — J.V. Aranda (PI) 8/10/00-8/9/02

• Schering Plough Research Institute A Phase IV Multicenter, Randomized, Parallel Group, Safety Study in Pediatric Subjects with Atopic Dermatitis Treated Once Daily for Three Weeks with Elocon Cream, Elocon Ointment or Elocon Lotion.

S3B30015 — J.V. Aranda (PI)2/10/00-4/30/01

• ICON Clinical Research An Eight-Week, Randomized, Double-Blind, Placebo-Controlled Study of Alosetron in Non-Constipated Adolescents with Irritable Bowel Syndrome.

S3B30019 — J.V. Aranda (PI) 2/10/00-4/30/01

• ICON Clinical Research A Sixteen-Week, Open-Label, Safety Study of Alosetron in Non-Constipated Adolescents with Irritable Bowel Syndrome.

gFEN-USA-87 — J.V. Aranda (PI) 11/16/99-11/16/02

• Janssen Pharmaceuticals, L.P. A Study to Assess the Safety, dose Conversion, and Titration of Duragesic (Fentanyl Transdermal System) in Pediatric Patients with Chronic Pain Requiring Opioid Therapy.